You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. New Cancer Vaccine Technology Based on DRibbles Produced by Tumor Cells

    SBC: UBIVAC, LLC            Topic: N/A

    DESCRIPTION (provided by applicant): Recent advances in cellular immunology have revolutionized our understanding of antigen processing and presentation. UBIVAC, LLC, has an exclusive option on technology (patent pending) that exploits these developments that was developed by Dr. Hong-Ming Hu. Further, the founders of UBIVAC (Drs. Hu and Fox) and their collaborators have investigated additional tr ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  2. Development of an Ad5 [E1-, E2b-] HIV-1 vaccine for use in Ad5 Immunized Vaccinee

    SBC: Etubics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): Current generation Adenovirus (Ad) vector vaccines deleted at the E1 or the E1, E3 regions have resulted in experimental potential to immunize against a variety of infectious diseases such as HIV. These Ad vectors permit the delivery of genes, which express proteins that stimulate the immune system. An advanced generation of Ad vectors with unique deletions of ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  3. ST-246 treatment of smallpox vaccine-related adverse events

    SBC: SIGA TECHNOLOGIES, INC.            Topic: N/A

    DESCRIPTION (provided by applicant): Naturally occurring smallpox has been eradicated but remains a credible threat to the security of the United States due to its potential use as an agent of terror or biowarfare. Given that approximately 25% of the population is contraindicated to receive the vaccine due to direct risk of adverse events or the possibility of placing direct contacts at risk (23), ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  4. A CD8+ T cell diagnostic to identify children with pulmonary tuberculosis

    SBC: ViTi, Inc            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB disease which results from infection with Mycobacterium tuberculosis Mtb is a leading cause of infectious morbidity and mortality in children andlt years old worldwide In TB endemic regions in which the vast majority of the worldandapos s annual million adult cases of TB disease reside children andlt years old account for ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  5. Correlating TCR diversity to immune reconstitution after cord blood transplant

    SBC: ADAPTIVE BIOTECHNOLOGIES CORPORATION            Topic: NHLBI

    DESCRIPTION (provided by applicant): Many patients requiring stem cell transplantation for hematological malignancies are unable to find a suitable HLA-matched sibling or unrelated donor. Transplants using stem cells from umbilical cord blood provide an alternative for these patients, allowing transplantation to proceed with less stringent HLA-matching requirements. Unfortunately, in addition to t ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  6. Development of a Novel CEA Expressing Ad5 [E1-, E2b-] Vector for Treatment

    SBC: Etubics Corporation            Topic: N/A

    DESCRIPTION (provided by applicant): The objective of this project is to continue to develop an adenoviral vector vaccine against CEA that is effective in stimulating cell-mediated immune responses in subjects previously immune to Adenovirus. The Ad-CEA vaccine endpoint is to treat patients with CEA bearing cancers. CEA is a tumor associated protein that has been reported to be useful as a vaccin ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  7. Tau Protein Aggregation Inhibitors for Tauopathies

    SBC: PROTEOTECH, INC.            Topic: NIA

    DESCRIPTION (provided by applicant): Alzheimer's disease (AD) is characterized by brain amyloid plaques consisting of insoluble beta-amyloid protein (A?), and neurofibrillary tangles (NFTs) containing aggregated tau protein. AD drug discovery efforts havebeen largely focused on reducing brain A? levels, with much less emphasis on tau-directed strategies. ProteoTech Inc. has developed a number ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  8. Reducing Complement Inhibition to Treat Leukemia and Lymphoma

    SBC: PAI LIFE SCIENCES INC            Topic: NCI

    DESCRIPTION (provided by applicant): Funding of this application will move a new combination cancer therapy for leukemia and lymphomas towards human clinical trials. Monoclonal antibodies, mAbs have emerged as a rapidly growing class of oncology therapeutics. Despite their success in certain clinical applications, the therapeutic efficacy of mAbs is limited, with only a minority of patients resp ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
  9. Internet Program to Prevent Postpartum Smoking Relapse

    SBC: Oregon Center For Applied Science, Inc            Topic: N/A

    DESCRIPTION (provided by applicant): About one third of women smokers stop smoking cigarettes when they become pregnant. Pregnancy therefore represents an important window of opportunity for these women to build upon their cessation success toward the goal of remaining smokefree for life. Unfortunately, the vast majority of these individuals resume smoking within a year postpartum, despite the fac ...

    SBIR Phase II 2009 Department of Health and Human ServicesNational Institutes of Health
  10. EGF/Gastrin for Islet Regeneration

    SBC: PHARMAIN CORPORATION            Topic: NIDDK

    DESCRIPTION (provided by applicant): New therapies are desperately needed to relieve patients with Type 1 diabetes from the neuropathy, nephropathy and retinopathy associated with the current standard of treatment, injected insulin. Transplantation of pancreatic islet -cells, in combination with immunosuppressant to avoid immune rejection, is restricted to a subgroup of diabetics and is limited b ...

    SBIR Phase II 2013 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government